Nesiritide

Nesiritide is the recombinant form of human B-type natriuretic peptide (BNP), a 32-amino-acid hormone normally synthesized and released by ventricular cardiomyocytes in response to volume overload and wall stress. Marketed under the brand name Natrecor, nesiritide received FDA approval in August 2001 for the treatment of acute decompensated heart failure (ADHF), and was notable at the time as the first genuinely new class of heart failure therapy in over two decades and the only recombinant protein among approved heart failure treatments.

At Verified Peptides, we want to highlight that nesiritide is one of the small number of compounds in this entire catalog with a real, complete FDA approval — manufactured via recombinant DNA technology in E. coli, with molecular formula C143H244N50O42S4 and molecular weight approximately 3,464 g/mol for the free peptide (nesiritide acetate, the salt form typically used in formulation, has CAS number 114471-18-0 and a slightly higher molecular weight around 3,524 g/mol due to the acetate counterion), PubChem CID 71308561.

Nesiritide's sequence is identical to endogenous human BNP, distinguishing it from many synthetic peptides in this catalog that are engineered analogs or fragments of a natural hormone — it is the natural hormone itself, produced recombinantly rather than extracted or chemically synthesized as a modified analog.

Endogenous BNP is synthesized as a larger 108-amino-acid precursor (proBNP), which is cleaved into the biologically active 32-amino-acid mature BNP and an inactive 76-amino-acid fragment called NT-proBNP. Both BNP and NT-proBNP are released into circulation in roughly equimolar amounts, and NT-proBNP, despite being biologically inactive, has become one of the most widely used clinical blood biomarkers for diagnosing and monitoring heart failure, precisely because its longer half-life makes it a more stable, easily measured surrogate for cardiac wall stress than active BNP itself. Nesiritide, as the recombinant mature hormone, is pharmacologically active in the same way endogenous BNP is, unlike the NT-proBNP fragment used diagnostically.

At Verified Peptides, we think nesiritide's full research and regulatory history is one of the most instructive case studies in this catalog, precisely because it illustrates how a genuinely FDA-approved drug's real-world reputation can shift dramatically based on subsequent evidence. Following the positive VMAC trial (PMID 11911755) and 2001 approval, nesiritide saw rapid, enthusiastic clinical adoption for ADHF.

In 2005, two meta-analyses published within weeks of each other substantially changed this picture. A renal-outcomes meta-analysis (Sackner-Bernstein et al., Circulation, 2005, PMID 15781736), pooling 5 randomized trials and 1,269 patients, found nesiritide at FDA-approved doses was associated with increased risk of worsening renal function compared to non-inotrope control therapy. A separate mortality meta-analysis (Sackner-Bernstein et al., JAMA, 2005, PMID 15840865), pooling 3 randomized trials and 862 patients, found 30-day mortality of 7.2% (35/485) in nesiritide-treated patients versus 4.0% (15/377) in controls — a risk ratio of 1.74. These findings triggered a rapid, dramatic decline in nesiritide's clinical use, extensively documented in a 2008 narrative review (Burnett and Korinek, Circulation: Heart Failure, PMID 19808264, titled "The Tumultuous Journey of Nesiritide").

The controversy was substantially resolved by a large, definitive trial: ASCEND-HF (O'Connor et al., New England Journal of Medicine, 2011, PMID 21732835), a randomized trial of over 7,000 ADHF patients, found that nesiritide neither increased nor decreased 30-day death or heart-failure rehospitalization, and did not worsen renal function or increase mortality — directly contradicting the earlier meta-analyses' safety signal, but also finding only modest symptomatic benefit rather than the dramatic efficacy some had hoped for. We think this arc — strong initial trial data, a genuine safety scare from meta-analyses of smaller trials, and a large definitive trial that found the drug safe but only modestly effective — is a valuable, honestly documented example of how evidence quality and trial size shape a drug's real clinical reputation over time.

At Verified Peptides, we sell research-grade nesiritide exclusively for laboratory research. As one of the relatively few genuinely FDA-approved compounds in this catalog, with an unusually well-documented and multi-stage evidence history, we think it offers researchers a particularly clear window into how natriuretic peptide biology translates (and sometimes doesn't fully translate) from mechanism to clinical outcome.

Nesiritide belongs to the natriuretic peptide family alongside atrial natriuretic peptide (ANP, released by atrial tissue) and C-type natriuretic peptide (CNP, primarily vascular/endothelial), all of which signal through related but distinct natriuretic peptide receptors — BNP and ANP both activate NPR-A, while CNP activates the separate NPR-B receptor. This family-wide structure is directly relevant to several other Phase 5 compounds in this catalog, including Urodilatin (a related natriuretic peptide of renal origin) and Apelin-13 (a separate but functionally related vasoactive/cardiovascular peptide system).

Nesiritide's manufacturing via E. coli recombinant expression, rather than mammalian cell culture, means the peptide itself is unglycosylated (BNP has no glycosylation sites in its core sequence, unlike many larger therapeutic proteins), simplifying its production relative to glycoprotein biologics but still requiring correct folding and disulfide bond formation (BNP contains an internal ring structure formed by a disulfide bond, a structural feature shared across the natriuretic peptide family and essential for receptor binding).

The 2005 nesiritide safety controversy is frequently cited in clinical pharmacology and evidence-based-medicine teaching contexts as a case study in the limitations of small-trial meta-analysis: the initial safety signal came from pooling several small trials with relatively few total events, a scenario known to be susceptible to producing statistically significant but ultimately non-replicated findings when a much larger, adequately powered trial (ASCEND-HF, with over 7,000 patients) is later conducted.

Despite the ASCEND-HF trial's reassuring safety findings, nesiritide's clinical use in the United States never fully returned to its pre-2005 volume, illustrating how a safety scare can permanently alter a drug's market position even after being substantially walked back by subsequent, more definitive evidence — a real-world lesson in the asymmetry between how quickly bad news spreads in clinical practice versus how slowly reassuring data changes established prescribing habits.

The FDA's 2001 approval decision for nesiritide came with a notable formal footnote: the agency required the manufacturer to conduct a large post-marketing outcomes trial, reflecting a degree of regulatory caution at the time of approval that was later validated by the 2005 safety controversy — an instructive example of how post-marketing surveillance requirements can be genuinely consequential rather than a mere formality, even though the eventual ASCEND-HF trial ultimately reassured rather than confirmed the initial safety concerns.

At Verified Peptides, we require independent third-party HPLC purity testing and mass spectrometry identity confirmation for every batch of research-grade nesiritide we offer, with a Certificate of Analysis (COA) available for each lot. As a 32-amino-acid recombinant peptide with an internal disulfide-bonded ring structure, correct folding and disulfide bond formation are essential to biological activity, making identity confirmation beyond simple amino acid composition analysis particularly important.

We source exclusively from manufacturers operating under Good Manufacturing Practice (GMP)-aligned quality systems, and every lot is independently verified rather than accepted solely on a supplier's internal documentation. Researchers should always request and review the specific COA for the lot they receive, confirming purity percentage and molecular identity, including correct disulfide bond formation where analytically verifiable, before use in any experimental protocol.

Lyophilized nesiritide is stable when stored at -20°C, protected from light and moisture, and researchers can generally expect the unreconstituted peptide to maintain integrity over an extended period under these conditions. At Verified Peptides, we ship lyophilized peptide with appropriate cold-chain packaging to preserve stability in transit.

Once reconstituted with sterile water or an appropriate diluent, nesiritide solution should be stored refrigerated at 2–8°C and used within the timeframe indicated on the product's documentation. Because nesiritide's activity depends on maintaining its internal disulfide-bonded ring structure, researchers should avoid conditions (such as reducing agents or repeated freeze-thaw cycling) that could disrupt this structure and compromise biological activity.

Researchers should follow the specific storage guidance provided with each lot's documentation to preserve sample validity, and avoid repeated freeze-thaw cycles of reconstituted material.